Comparative Pharmacology
Head-to-head clinical analysis: COLYTE WITH FLAVOR PACKS versus COLYTE FLAVORED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COLYTE WITH FLAVOR PACKS versus COLYTE FLAVORED.
COLYTE WITH FLAVOR PACKS vs COLYTE-FLAVORED
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Colyte is an isotonic solution containing polyethylene glycol 3350 and electrolytes. It acts as an osmotic laxative by retaining water in the colon through non-absorbable polyethylene glycol, resulting in bowel evacuation. The electrolytes prevent significant fluid and electrolyte shifts.
Colyte is an osmotic laxative that induces diarrhea by retaining water in the colon through non-absorbable polyethylene glycol (PEG) and electrolytes, resulting in bowel cleansing.
Bowel cleansing prior to colonoscopy or barium enema
Colonoscopy preparationBowel cleansing prior to colorectal surgeryBowel preparation for barium enema
Adults: 4 liters of reconstituted solution administered orally or via nasogastric tube at a rate of 240 mL every 10 minutes, given as a single dose or in divided doses for colonoscopy preparation.
4 liters orally as a single dose or in divided doses for colonoscopy preparation, or 1 liter orally every 10-15 minutes until 4 liters are consumed.
None Documented
None Documented
Not applicable (non-absorbed; no systemic absorption, thus no elimination half-life in plasma).
Not applicable; the drug acts locally in the gastrointestinal tract without significant systemic absorption. For the small fraction absorbed, a terminal elimination half-life of approximately 0.5-1 hour is estimated, but clinical relevance is negligible.
Polyethylene glycol 3350 is minimally absorbed and not metabolized; it is excreted unchanged in feces. Electrolytes are absorbed and metabolized normally.
Polyethylene glycol (PEG) is not significantly metabolized; it is excreted unchanged in feces.
Primarily fecal (100%) as non-absorbed oral solution; negligible renal or biliary elimination.
Primarily eliminated in feces (≥95%) as intact drug via the gastrointestinal tract. Minimal systemic absorption; renal excretion accounts for <1% of the administered dose.
Not applicable (non-absorbed; no systemic exposure).
Negligible (<5%) due to minimal systemic absorption; no specific binding proteins identified.
Not applicable (non-absorbed; no systemic distribution).
Not meaningful due to negligible systemic absorption. The small fraction absorbed distributes primarily in extracellular fluid; a theoretical Vd would be low (<0.2 L/kg), but not clinically relevant.
Oral: negligible systemic bioavailability (<0.1%) due to minimal absorption of polyethylene glycol and electrolytes.
Oral bioavailability is <1% due to minimal gastrointestinal absorption; the drug acts locally within the intestinal lumen.
No dose adjustment required for renal impairment; however, use with caution in patients with severe renal impairment (GFR <30 mL/min) due to risk of fluid and electrolyte abnormalities.
Use with caution in patients with GFR <30 mL/min/1.73 m2; consider alternative bowel preparation. No specific dose adjustment defined.
No specific dose adjustment for hepatic impairment; use standard dosing with caution in severe liver disease due to potential fluid shifts.
No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to risk of fluid and electrolyte disturbances.
Pediatric patients: 25-40 mL/kg/hour until rectal effluent is clear; maximum 4 liters total. Safety and efficacy not established for children under 6 months.
Not recommended for use in children; safety and efficacy not established.
Elderly: Consider reduced volume (e.g., 2-3 liters) and slower administration rate (e.g., 240 mL every 20 minutes) to mitigate risk of aspiration and electrolyte imbalance.
Use with caution; monitor for fluid and electrolyte imbalances, renal function, and volume status. Consider lower dose or split-dose regimen.
WARNING: SERIOUS FLUID AND ELECTROLYTE ABNORMALITIES, SEIZURES, AND CARDIAC ARRHYTHMIAS. Use with caution in patients at risk for these conditions. Monitor fluid and electrolyte status.
There is no FDA black box warning for Colyte.
["Risk of aspiration, especially in patients with impaired gag reflex or reduced level of consciousness","Fluid and electrolyte disturbances (e.g., hyponatremia, hypokalemia) may occur; monitor in patients with renal or hepatic impairment, heart failure, or those taking diuretics or other drugs affecting electrolytes","Seizures and cardiac arrhythmias have been reported, often in patients with electrolyte imbalances or taking medications that lower seizure threshold","Mucosal ulcerations may occur; avoid use in patients with active inflammatory bowel disease or toxic megacolon","Arrhythmias (e.g., atrial fibrillation, QT prolongation) have been reported","Upper GI bleeding or obstruction; contraindicated in gastric retention or obstruction"]
["Risk of aspiration and esophageal perforation in patients with impaired gag reflex or altered consciousness","Electrolyte disturbances (e.g., hypernatremia, hypokalemia) in patients with renal impairment or dehydration","Cardiac arrhythmias in patients with electrolyte imbalances or QT prolongation","Colonic mucosal erosions or ulcerations with repeated use","Not for use in patients with gastrointestinal obstruction, perforation, or ileus"]
["Gastrointestinal obstruction or ileus","Gastric retention or perforation","Bowel perforation","Toxic colitis or toxic megacolon","Hypersensitivity to any component"]
["Gastrointestinal obstruction","Gastric retention","Bowel perforation","Toxic colitis","Toxic megacolon","History of severe electrolyte abnormalities","Known hypersensitivity to any component"]
Data Pending Review
Data Pending Review
Avoid all solid foods and dairy products during bowel preparation. Only clear liquids (e.g., water, clear broth, black coffee, tea without milk, clear fruit juices without pulp, gelatin) are permitted. Do not consume red or purple liquids as they may be mistaken for blood during colonoscopy. Alcohol should be avoided for at least 24 hours prior to the procedure.
Only clear liquids are allowed during bowel preparation. Avoid milk, cream, soups with solid ingredients, red or purple liquids, and alcohol. Solid food should be avoided at least 2 hours before starting the solution. No food interactions with the drug itself; dietary restrictions are for the procedure.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. Polyethylene glycol (PEG) is not systemically absorbed; minimal fetal exposure expected. Electrolyte shifts could theoretically affect fetal fluid balance, but no known teratogenicity. First trimester: low risk based on lack of systemic absorption. Second/third trimester: theoretical risk of maternal electrolyte imbalance affecting fetal homeostasis, though no specific fetal adverse effects reported.
Category C: Not associated with major malformations; limited data in pregnancy. No known teratogenicity; use only if clearly needed.
PEG is not absorbed systemically, thus minimal excretion into breast milk. M/P ratio not applicable/unknown. Considered compatible with breastfeeding as a bowel preparation, but caution with large volumes may alter maternal fluid/electrolyte status, indirectly affecting milk production or composition. Use only if clearly needed.
Excretion unknown; likely minimal systemic absorption. No M/P ratio available. Use with caution.
No specific pharmacokinetic changes in pregnancy requiring dose adjustment due to lack of systemic absorption. However, decreased gastrointestinal motility in pregnancy may prolong colonic transit time; no dose change recommended but monitor for tolerance. Use standard dosing (e.g., 4L in split dose) as in non-pregnant adults, with attention to hydration.
No dosage adjustment required; monitor for hypovolemia due to increased plasma volume.
Category C
Category C
Colyte with Flavor Packs is a polyethylene glycol 3350-based osmotic laxative used for bowel cleansing prior to colonoscopy. Ensure adequate hydration before, during, and after administration. Do not use flavor packs containing aspartame in patients with phenylketonuria. Monitor for electrolyte imbalances in patients with renal impairment or those on diuretics. Discontinue if severe bloating, abdominal pain, or vomiting occurs.
Colyte-Flavored (PEG-3350 and electrolytes) is a colonic lavage solution used for bowel preparation prior to colonoscopy. Ensure adequate hydration: patients must consume all 4 liters (or split-dose regimen). Concurrent use of other laxatives or enemas is generally not needed. In patients with impaired gag reflex, renal insufficiency, or electrolyte abnormalities, use with caution. Monitor for bloating, nausea, and aspiration risk. Avoid use in GI obstruction, toxic colitis, or megacolon.
Do not eat any solid food after starting the preparation; only clear liquids are allowed.Mix the powder with water as directed and refrigerate to improve taste.Drink the entire solution at the prescribed rate; set a timer if needed.Expect watery stools; stay near a bathroom during the cleansing process.Do not add extra flavorings or sweeteners unless provided in the pack.Contact your doctor if you experience severe nausea, vomiting, or inability to keep the solution down.
Do not add any other ingredients to the solution.Chill the solution before drinking to improve palatability.Drink the entire volume over the prescribed period; do not eat solid foods until after the procedure.Expect frequent, watery bowel movements; stay near a toilet.Take other medications at least 1 hour before starting the solution, except as directed by your doctor.Stop drinking the solution 2-3 hours before the procedure.If severe bloating, abdominal pain, or vomiting occurs, pause and resume later.